Hippo(crates): An integrated atlas for natural product exploration through a state‑of‑the art pipeline in chemoinformatics

Papageorgiou,Louis; Andreou,Athena; Christoforides,Elias; Bethanis,Kostas; Vlachakis,Dimitrios; Thireou,Trias; Eliopoulos,Elias

doi:10.3892/wasj.2021.136

Hippo(crates): An integrated atlas for natural product exploration through a state‑of‑the art pipeline in chemoinformatics

Authors:
- Louis Papageorgiou
- Athena Andreou
- Elias Christoforides
- Kostas Bethanis
- Dimitrios Vlachakis
- Trias Thireou
- Elias Eliopoulos
View Affiliations

Affiliations: Department of Biotechnology, Genetics Laboratory, School of Applied Biology and Biotechnology, Agricultural University of Athens, 11855 Athens, Greece, Department of Biotechnology, Physics Laboratory, School of Applied Biology and Biotechnology, Agricultural University of Athens, 11855 Athens, Greece
Published online on: November 8, 2021 https://doi.org/10.3892/wasj.2021.136
Article Number: 1
Copyright: © Papageorgiou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Modern drug discovery and pharmaceutics benefit from nature. Natural products (NPs) are used as a source of therapeutic agents with beneficial uses. Currently, there is considerable interest in the exploration of NPs for drug discovery and continuous investigations on the therapeutic claims and mechanisms of herbal medicines. To date, approximately one million NPs have been isolated and subjected to experimental assays to evaluate quantitative biological activities. This renders the use of an integrated database to assemble and correlate this valuable information from the literature, experimental studies and databases necessary. Although databases contain a large volume of information, it is frequently difficult and complex, even in well‑organized databases, to extract the required information. Novel databases must be accompanied by efficient algorithms and techniques in order to extract beneficial knowledge by a simple query. The Hippo(crates) database aims to fill this gap in the field of chemoinformatics and natural products by providing retrieval not only linked to the Hippo(crates) database, but also to other worldwide chemical and biological databases. Part of the OPENSCREEN‑GR project, the Hippo(crates) Database Graphical User Interface (HDGUI) web server was developed to provide a user‑friendly access interface, integrating annotated information of NP origin (sources and species), biological activities, physicochemical properties, linear and 3D chemical structure, as well as relative terms that correlate chemical compounds and their use. In its current version (V1.0), the Hippo database provides 45,300 NPs, NP derivatives and synthetic compounds, which are separated into 32 major categories, including biological or medicinal properties. In the database, 22,830 NP source organisms are correlated, with >100,000 terms, including biological pathways, target organisms, target diseases, target types, target proteins and pathogens, and 6,070 three‑dimensional structures of NP target proteins. For each entry, a cluster with similar compounds and a ligand‑based or structure‑based pharmacophore model is provided. The portal is designed as an easy‑to‑use web tool where the user can easily search, extract and correlate information and data for natural product chemical compounds through various fields, such as categories, keywords, targets, species, or two‑dimensional or three‑dimensional similarity structure in the Hippo(crates) atlas of the NP database.

View Figures

View References

1	Hong J: Role of natural product diversity in chemical biology. Curr Opin Chem Biol. 15:350–354. 2011.PubMed/NCBI View Article : Google Scholar
2	Bernardini S, Tiezzi A, Laghezza Masci V and Ovidi E: Natural products for human health: An historical overview of the drug discovery approaches. Nat Prod Res. 32:1926–1950. 2018.PubMed/NCBI View Article : Google Scholar
3	Beutler JA: Natural Products as a Foundation for Drug Discovery. Curr Protoc Pharmacol. 46:9.11.1–9.11.21. 2009.PubMed/NCBI View Article : Google Scholar
4	Newman DJ and Cragg GM: Natural products as sources of new drugs over the last 25 years. J Nat Prod. 70:461–477. 2007.PubMed/NCBI View Article : Google Scholar
5	Thomford NE, Senthebane DA, Rowe A, Munro D, Seele P, Maroyi A and Dzobo K: Natural Products for Drug Discovery in the 21st Century: Innovations for Novel Drug Discovery. Int J Mol Sci. 19(E1578)2018.PubMed/NCBI View Article : Google Scholar
6	Kayser O, Kiderlen AF and Croft SL: Natural products as antiparasitic drugs. Parasitol Res. 90 (Suppl 2):S55–S62. 2003.PubMed/NCBI View Article : Google Scholar
7	Salam AM and Quave CL: Opportunities for plant natural products in infection control. Curr Opin Microbiol. 45:189–194. 2018.PubMed/NCBI View Article : Google Scholar
8	Sut S, Dall'Acqua S, Zengin G, Senkardes I, Bulut G, Cvetanović A, Stupar A, Mandić A, Picot-Allain C, Dogan A, et al: Influence of different extraction techniques on the chemical profile and biological properties of Anthemis cotula L.: Multifunctional aspects for potential pharmaceutical applications. J Pharm Biomed Anal. 173:75–85. 2019.PubMed/NCBI View Article : Google Scholar
9	Salis C, Papageorgiou L, Papakonstantinou E, Hagidimitriou M and Vlachakis D: Olive Oil Polyphenols in Neurodegenerative Pathologies. Adv Exp Med Biol. 1195:77–91. 2020.PubMed/NCBI View Article : Google Scholar
10	Treml J, Gazdová M, Šmejkal K, Šudomová M, Kubatka P and Hassan STS: Natural Products-Derived Chemicals: Breaking Barriers to Novel Anti-HSV Drug Development. Viruses. 12(E154)2020.PubMed/NCBI View Article : Google Scholar
11	Koumandou VL, Papageorgiou L, Tsaniras SC, Papathanassopoulou A, Hagidimitriou M, Cosmidis N and Vlachakis D: Microbiome Hijacking Towards an Integrative Pest Management Pipeline. Adv Exp Med Biol. 1195:21–32. 2020.PubMed/NCBI View Article : Google Scholar
12	Kong DX, Li XJ and Zhang HY: Where is the hope for drug discovery? Let history tell the future. Drug Discov Today. 14:115–119. 2009.PubMed/NCBI View Article : Google Scholar
13	Wagner H and Ulrich-Merzenich G: Synergy research: Approaching a new generation of phytopharmaceuticals. Phytomedicine. 16:97–110. 2009.PubMed/NCBI View Article : Google Scholar
14	Calixto JB: The role of natural products in modern drug discovery. An Acad Bras Cienc. 91 (Suppl 3)(e20190105)2019.PubMed/NCBI View Article : Google Scholar
15	Newman DJ and Cragg GM: Natural Products as Sources of New Drugs from 1981 to 2014. J Nat Prod. 79:629–661. 2016.PubMed/NCBI View Article : Google Scholar
16	Agrafiotis DK, Bandyopadhyay D, Wegner JK and Vlijmen H: Recent advances in chemoinformatics. J Chem Inf Model. 47:1279–1293. 2007.PubMed/NCBI View Article : Google Scholar
17	Lo YC, Rensi SE, Torng W and Altman RB: Machine learning in chemoinformatics and drug discovery. Drug Discov Today. 23:1538–1546. 2018.PubMed/NCBI View Article : Google Scholar
18	Muegge I and Mukherjee P: An overview of molecular fingerprint similarity search in virtual screening. Expert Opin Drug Discov. 11:137–148. 2016.PubMed/NCBI View Article : Google Scholar
19	Fernandes JPS: The Importance of Medicinal Chemistry Knowledge in the Clinical Pharmacist's Education. The Importance of Medicinal Chemistry Knowledge in the Clinical Pharmacist's Education. Am J Pharm Educ. 82(6083)2018.PubMed/NCBI View Article : Google Scholar
20	Mitsis T, Papageorgiou L, Efthimiadou A, Bacopoulou F, Vlachakis D, Chrousos GP and Eliopoulos E: A comprehensive structural and functional analysis of the ligand binding domain of the nuclear receptor superfamily reveals highly conserved signaling motifs and two distinct canonical forms through evolution. World Acad Sci J. 1:264–274. 2019.
21	Papageorgiou L, Shalzi L, Pierouli K, Papakonstantinou E, Manias S, Dragoumani K, Nicolaides N, Giannakakis A, Bacopoulou F, Chrousos G, et al: An updated evolutionary study of the nuclear receptor protein family. World Acad Sci J. 3(51)2021.
22	Chaudhari R, Tan Z, Huang B and Zhang S: Computational polypharmacology: A new paradigm for drug discovery. Expert Opin Drug Discov. 12:279–291. 2017.PubMed/NCBI View Article : Google Scholar
23	Pushpakom S, Iorio F, Eyers PA, Escott KJ, Hopper S, Wells A, Doig A, Guilliams T, Latimer J, McNamee C, et al: Drug repurposing: Progress, challenges and recommendations. Nat Rev Drug Discov. 18:41–58. 2019.PubMed/NCBI View Article : Google Scholar
24	Vlachakis D, Papageorgiou L, Papadaki A, Georga M, Kossida S and Eliopoulos E: An updated evolutionary study of the Notch family reveals a new ancient origin and novel invariable motifs as potential pharmacological targets. PeerJ. 8(e10334)2020.PubMed/NCBI View Article : Google Scholar
25	Awale M, Visini R, Probst D, Arús-Pous J and Reymond JL: Chemical Space: Big Data Challenge for Molecular Diversity. Chimia (Aarau). 71:661–666. 2017.PubMed/NCBI View Article : Google Scholar
26	Voigt JH, Bienfait B, Wang S and Nicklaus MC: Comparison of the NCI open database with seven large chemical structural databases. J Chem Inf Comput Sci. 41:702–712. 2001.PubMed/NCBI View Article : Google Scholar
27	Wishart DS, Knox C, Guo AC, Cheng D, Shrivastava S, Tzur D, Gautam B and Hassanali M: DrugBank: A knowledgebase for drugs, drug actions and drug targets. Nucleic Acids Res. 36 (Suppl 1):D901–D906. 2008.PubMed/NCBI View Article : Google Scholar
28	Wishart DS, Feunang YD, Guo AC, Lo EJ, Marcu A, Grant JR, Sajed T, Johnson D, Li C, Sayeeda Z, et al: DrugBank 5.0: A major update to the DrugBank database for 2018. Nucleic Acids Res. 46 (D1):D1074–D1082. 2018.PubMed/NCBI View Article : Google Scholar
29	Zeng X, Zhang P, He W, Qin C, Chen S, Tao L, Wang Y, Tan Y, Gao D, Wang B, et al: NPASS: Natural product activity and species source database for natural product research, discovery and tool development. Nucleic Acids Res. 46 (D1):D1217–D1222. 2018.PubMed/NCBI View Article : Google Scholar
30	Choi H, Cho SY, Pak HJ, Kim Y, Choi JY, Lee YJ, Gong BH, Kang YS, Han T, Choi G, et al: NPCARE: Database of natural products and fractional extracts for cancer regulation. J Cheminform. 9(2)2017.PubMed/NCBI View Article : Google Scholar
31	Cheng S, Zhu C, Chu C, Huang T, Kong X and Zhu LC: Prediction of bioactive compound pathways using chemical interaction and structural information. Comb Chem High Throughput Screen. 19:161–169. 2016.PubMed/NCBI View Article : Google Scholar
32	Ihlenfeldt WD, Voigt JH, Bienfait B, Oellien F and Nicklaus MC: Enhanced CACTVS browser of the Open NCI Database. J Chem Inf Comput Sci. 42:46–57. 2002.PubMed/NCBI View Article : Google Scholar
33	Knox C, Law V, Jewison T, Liu P, Ly S, Frolkis A, Pon A, Banco K, Mak C, Neveu V, et al: DrugBank 3.0: A comprehensive resource for ‘omics’ research on drugs. Nucleic Acids Res. 39 (Database):D1035–D1041. 2011.PubMed/NCBI View Article : Google Scholar
34	Hähnke VD, Kim S and Bolton EE: PubChem chemical structure standardization. J Cheminform. 10(36)2018.PubMed/NCBI View Article : Google Scholar
35	Heller SR, McNaught A, Pletnev I, Stein S and Tchekhovskoi D: InChI, the IUPAC International Chemical Identifier. J Cheminform. 7(23)2015.PubMed/NCBI View Article : Google Scholar
36	Reyes-Aldasoro CC: The proportion of cancer-related entries in PubMed has increased considerably; is cancer truly ‘The Emperor of All Maladies’? PLoS One. 12(e0173671)2017.PubMed/NCBI View Article : Google Scholar
37	Dunn MJ, Jorde LB, Little PFR and Subramaniam S (eds): Encyclopedia of Genetics, Genomics, Proteomics and Bioinformatics, 8 Volume Set. John Wiley & Sons Ltd., Hoboken NJ, 2005.
38	Vilar S, Cozza G and Moro S: Medicinal chemistry and the molecular operating environment (MOE): Application of QSAR and molecular docking to drug discovery. Curr Top Med Chem. 8:1555–1572. 2008.PubMed/NCBI View Article : Google Scholar
39	Mhlanga P, Wan Hassan WA, Hamerton I and Howlin BJ: Using combined computational techniques to predict the glass transition temperatures of aromatic polybenzoxazines. PLoS One. 8(e53367)2013.PubMed/NCBI View Article : Google Scholar
40	Ihlenfeldt WD, Takahashi Y, Abe H and Sasaki S: Computation and management of chemical properties in CACTVS: An extensible networked approach toward modularity and compatibility. J Chem Inf Comput Sci. 34:109–116. 1994.
41	Huggins DJ, Venkitaraman AR and Spring DR: Rational methods for the selection of diverse screening compounds. ACS Chem Biol. 6:208–217. 2011.PubMed/NCBI View Article : Google Scholar
42	Hudson BD, Hyde RM, Rahr E, Wood J and Osman J: Parameter Based Methods for Compound Selection from Chemical Databases. Quant Struct-Act Rel. 15:285–289. 1996.
43	Bajusz D, Rácz A and Héberger K: Why is Tanimoto index an appropriate choice for fingerprint-based similarity calculations? J Cheminform. 7(20)2015.PubMed/NCBI View Article : Google Scholar
44	Wolber G and Langer T: LigandScout: 3-D pharmacophores derived from protein-bound ligands and their use as virtual screening filters. J Chem Inf Model. 45:160–169. 2005.PubMed/NCBI View Article : Google Scholar
45	Shaker B, Yu MS, Lee J, Lee Y, Jung C and Na D: User guide for the discovery of potential drugs via protein structure prediction and ligand docking simulation. J Microbiol. 58:235–244. 2020.PubMed/NCBI View Article : Google Scholar
46	Zhou Y, Tang S, Chen T and Niu MM: Structure-Based Pharmacophore Modeling, Virtual Screening, Molecular Docking and Biological Evaluation for Identification of Potential Poly. Structure-Based Pharmacophore Modeling, Virtual Screening, Molecular Docking and Biological Evaluation for Identification of Potential Poly (ADP-Ribose) Polymerase-1 (PARP-1) Inhibitors. Molecules. 24(E4258)2019.PubMed/NCBI View Article : Google Scholar
47	Bolton EE, Chen J, Kim S, Han L, He S, Shi W, Simonyan V, Sun Y, Thiessen PA, Wang J, et al: PubChem3D: A new resource for scientists. J Cheminform. 3(32)2011.PubMed/NCBI View Article : Google Scholar
48	Kim S, Bolton EE and Bryant SH: Similar compounds versus similar conformers: Complementarity between PubChem 2-D and 3-D neighboring sets. J Cheminform. 8(62)2016.PubMed/NCBI View Article : Google Scholar
49	Wachtel-Galor S, Yuen J, Buswell JA and Benzie IFF: Ganoderma lucidum (Lingzhi or Reishi): A Medicinal Mushroom. In: Herbal Medicine: Biomolecular and Clinical Aspects. Benzie IFF and Wachtel-Galor S (eds). 2nd edition. CRC Press/Taylor & Francis, Boca Raton, FL, 2011.
50	Xu J, Chen F, Wang G, Liu B, Song H and Ma T: The Versatile Functions of G. Lucidum Polysaccharides and G. Lucidum Triterpenes in Cancer Radiotherapy and Chemotherapy. Cancer Manag Res. 13:6507–6516. 2021.PubMed/NCBI View Article : Google Scholar
51	Papageorgiou L, Zervou MI, Vlachakis D, Matalliotakis M, Matalliotakis I, Spandidos DA, Goulielmos GN and Eliopoulos E: Demetra Application: An integrated genotype analysis web server for clinical genomics in endometriosis. Int J Mol Med. 47(115)2021.PubMed/NCBI View Article : Google Scholar
52	Spreafico R, Soriaga LB, Grosse J, Virgin HW and Telenti A: Advances in Genomics for Drug Development. Genes (Basel). 11(E942)2020.PubMed/NCBI View Article : Google Scholar
53	Cardon LR and Harris T: Precision medicine, genomics and drug discovery. Hum Mol Genet. 25 (R2):R166–R172. 2016.PubMed/NCBI View Article : Google Scholar
54	Sonehara K and Okada Y: Genomics-driven drug discovery based on disease-susceptibility genes. Inflamm Regen. 41(8)2021.PubMed/NCBI View Article : Google Scholar